Advertisement

Tumor Biology

, Volume 33, Issue 5, pp 1701–1707 | Cite as

Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion

  • Mohamed Y. Elsammak
  • Adel Attia
  • Hoda A. Hassan
  • Taysser M. Zaytoun
  • Mahmoud Shorman
  • Moosa Suleman
Research Article

Abstract

Pleural effusion is a commonly encountered problem in clinical practice, and pleural fluid analysis is usually the first step towards identifying the underlying etiology. Numerous studies have been published analyzing the potential utility of measuring biomarkers in pleural fluid as possible indicators of a malignant effusion; however, there are no studies that have examined the presence of human epididymis 4 (HE4) in pleural effusions. The aims of this study were to assess pleural effusion and serum concentrations of HE4 in patients with different types of pleural effusions and to evaluate the diagnostic performance of HE4 in detecting malignant pleural effusion. A prospective cohort study was carried out of 88 consecutive patients presenting with pleural effusions. The patients were divided into three groups: 22 patients with transudative effusions, 32 patients with non-malignant exudative effusions, and 34 patients with malignant pleural effusions. Blood and pleural fluid HE4 levels were measured using immunoassay. Both serum HE4 levels and pleural effusion HE4 levels were significantly higher in patients with malignant effusions than in patients with transudative or non-malignant exudative effusions. A pleural fluid HE4 cutoff value of 1,675 pmol/L was found to predict malignant pleural effusions with a diagnostic sensitivity of 85.3 % and specificity of 90.7 %. The current study reports a novel finding of increased serum and pleural fluid HE4 levels in patients with malignant effusions compared to non-malignant effusions. This finding has the potential to strengthen the diagnostic performance of tumor markers in detecting malignant pleural effusions.

Keywords

Human epididymis 4 (HE4) Pleural effusion 

Notes

Conflicts of interest

None

References

  1. 1.
    Murphy MJ, Jenkinson F. Categorisation of pleural fluids in routine clinical practice: analysis of pleural fluid protein and lactate dehydrogenase alone compared with modified Light's criteria. J Clin Pathol. 2008;61:684–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Light RW, Mac Gregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. 1997;111:970–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320–4.PubMedGoogle Scholar
  5. 5.
    Garcia L. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994;7(3):665e8.Google Scholar
  6. 6.
    Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology. 2010;42:224–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Hackbarth JS, Murata K, Reilly WM, Algeciras-Schimnich A. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies. Clin Biochem. 2010;43:1051–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Bouchard D, Morisset D, Bourbonnais Y, et al. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006;7:167–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45:350–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN. Aerts J Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat. 2009;8:323–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32:1087–95.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi R, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppanen M, Grenman S. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.PubMedGoogle Scholar
  17. 17.
    Drapkin R, Von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Tokuishi K, Yamashita SI, Ohbo K, Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumour Biol. 2012;33:103–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Antunes G, Neville E, Duffy J, Ali N, Pleural Diseases Group. BTS guidelines for the management of malignant pleural effusions. Standards of Care Committee, British Thoracic Society. Thorax. 2003;58 Suppl 2:ii29–38.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Korczynski P, Krenke R, Safianowska A, Gorska K, Abou Chaz MB, Maskey-Warzechowska M, Kondracka A, Nasilowski J, Chazan R. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res.;14 Suppl 4:128-33.Google Scholar
  22. 22.
    Gaspar MJ, De Miguel J, García Díaz JD, Díez M. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res. 2008;28:2947–52.PubMedGoogle Scholar
  23. 23.
    Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem. 2009;42:1046–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Kalantri Y, Naik G, Joshi SP, Jain A, Phatak S, Chavan R, Hemvani N. Chitnis DS Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions. Indian J Med Res. 2007;125:25–30.PubMedGoogle Scholar
  25. 25.
    Einhorn N, Sjovall K, Knapp RC, Hall P, Soully RE, Bast Jr RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14–8.PubMedGoogle Scholar
  26. 26.
    Rubin J, Rockey DC. Cirrhotic ascites. Ovarian carcinoma and CA125. South Med J. 1999;92:248–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Trapé J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol. 2004;25:276–81.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Mohamed Y. Elsammak
    • 1
    • 6
  • Adel Attia
    • 2
    • 9
  • Hoda A. Hassan
    • 3
    • 7
  • Taysser M. Zaytoun
    • 4
    • 8
  • Mahmoud Shorman
    • 5
  • Moosa Suleman
    • 2
  1. 1.Department of Chemical PathologyKing Fahad Specialist Hospital DammamDammamSaudi Arabia
  2. 2.Department of PulmonologyKing Fahad Specialist Hospital DammamDammamSaudi Arabia
  3. 3.Department of MicrobiologyKing Fahad Specialist Hospital DammamDammamSaudi Arabia
  4. 4.Department of Critical CareKing Fahad Specialist Hospital DammamDammamSaudi Arabia
  5. 5.Department of Internal MedicineKing Fahad Specialist Hospital DammamDammamSaudi Arabia
  6. 6.Department of Chemical Pathology, Medical Research InstituteAlexandria UniversityAlexandriaEgypt
  7. 7.Department of MicrobiologyAlexandria UniversityAlexandriaEgypt
  8. 8.Department of Critical care Faculty of MedicineAlexandria UniversityAlexandriaEgypt
  9. 9.Department of Chest, Faculty of MedicineZagazig UniversityZagazigEgypt

Personalised recommendations